Avacta sees surging Optim sales

DIAGNOSTICS group Avacta said sales of its flagship Optim device have increased 50 per cent and is exploring further expansion.

The Wetherby-based group, spun out of the University of Leeds, said a programme to improve margins on Optim sales is also underway.

Optim is designed to speed up and reduce the cost of drug development. It is claimed to deliver vital information tens times faster than other approaches using much smaller samples.

Hide Ad
Hide Ad

Avacta added early revenues from disposable cartridges for Optim are “encouraging”.

“In the first full year of working, the group has invested significant efforts into training and support of its partners and has addressed logistical challenges that have arisen,” it said.

“The group now anticipates realising the benefits of this investment in a more streamlined infrastructure and sales process as these agreements progress.

“Avacta continues to explore opportunities and expansion into further territories and will update the market accordingly.”

Optim sales initially progressed slower than hoped for, and Avacta also had to contend with production problems with the plastic disposable cartridges for its AX-1 diagnostics device.